Andrea Lobo,  —

An oral spray was safe and efficient at delivering apomorphine to people with Parkinson’s disease, a study found. A subcutaneous injection formulation of apomorphine, sold as Apokyn, is approved in the U.S. to treat off episodes — periods in which symptoms return between doses of levodopa treatment — in…

A region in the alpha-synuclein protein has been identified as a possible target for inhibiting the conversion of oligomers — early aggregates, or clumps, of the protein — into toxic fibrils, a hallmark of Parkinson’s disease, according to a recent study. Mutations in this region are also associated with…

Aspen Neuroscience has been awarded an $8 million grant to advance the clinical development of ANPD001, its investigational stem cell therapy that’s designed to replace dopamine-producing nerve cells lost in Parkinson’s disease. The grant, funded by the California Institute for Regenerative Medicine (CIRM), will support the ongoing Phase…

Enhancing mechanisms associated with the degradation of misfolded proteins at the proteasome, that is, cellular structures where these proteins are degraded, may be a new therapeutic target for neurodegenerative diseases, including Parkinson’s disease. That’s according to a new study in fruit flies, where researchers found that the ZIP7 protein,…

The first 25 patients have been enrolled in a Phase 3 trial that’s testing the light-based, at-home therapy device called Celeste for treating Parkinson’s disease, its developer PhotoPharmics has announced. The “Celeste Light for PD Trial” is evaluating the device’s safety and effectiveness at easing both motor…

A newly developed molecule showed an ability in lab studies to activate antioxidant responses in brain cells by altering how two proteins, believed to be involved in the development of Parkinson’s disease and other neurodegenerative conditions, interact. The small molecule, known as a protein-like polymer, is designed to bind to…

Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is now expected in June, Annovis Bio, the therapy’s developer, has disclosed. While Annovis originally planned to share its early findings at the beginning of this year, the company faced…

Researchers in Canada have developed a new method to generate functional dopaminergic neurons, the dopamine-producing nerve cells lost in Parkinson’s disease, from human pluripotent stem cells (hPSC). The scientists used an antibody to selectively activate FZD5, a receptor, in the stem cells, which stimulated a specific molecular signaling pathway involved…

After adding $47 million in new funding, Cerevance is planning to launch a Phase 3 clinical trial to test its oral molecule CVN424, designed to treat people with early-stage Parkinson’s disease without the side effects seen with other therapies, the company announced in a press release. That…

People who carry a specific mutation in the RAB32 gene have a higher risk of developing Parkinson’s disease, researchers at the University of Florida found. The mutation, called RAB32 Ser71Arg, was identified in 16 individual families from different ethnic groups and increased the activation of the LRRK2 protein, a…